Drug Trial Radar · NCT07211685
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 19, 2025
Primary completion
Nov 29, 2027
Study completion Nov 29, 2027
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS. The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.
Conditions
- Alport Syndrome
Interventions
BAY 3401016Drug
BAY 3401016
PlaceboOther
Placebo to BAY 3401016
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary albumin creatinine ratio (UACR) ratio to baseline averaged over 16, 20 and 24 weeks of treatmentTime frame: From the start of study intervention, over 16, 20 and 24 weeks of treatment, until the last follow-up visit, 90 days ± 3 days after EoT
Locations
51 sites in 15 countries. Site status is shown where the registry gives one.
Nephrology Clinic at The Kirklin Clinic of UAB Hospital
Birmingham, Alabama
The Peggy and Harold Katz Family Drug Discovery Center - Nephrology
Miami, Florida
Cardio Renal Institute
Chubbuck, Idaho
Tufts Medical Center | Nephrology Department
Boston, Massachusetts
Renal Disease Research Institute | Landry
Dallas, Texas
Hospital Británico
Buenos Aires, Argentina
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
Buenos Aires, Argentina
Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
San Luis, Argentina
Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares S.A.
Santa Fe, Santa Fe Province, Argentina
Centre hospitalier universitaire de Québec (CHUQ) | Nephrology
Québec, Canada
St Joseph's Healthcare Hamilton | Cardiology
Hamilton, Ontario, Canada
Montreal General Hospital | Nephrology
Montreal, Quebec, Canada
Peking University First Hospital - Department of Pediatrics
Beijing, Beijing Municipality, China
The First Affiliated Hospital, Sun Yat-sen University - Department of Pediatrics
Guangzhou, Guangdong, China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Pediatric Nephrology and Immunology
Wuhan, Hubei, China
Children's Hospital, Zhejiang University School of Medicine - Department of Nephrology
Hangzhou, Zhejiang, China
Fakultní nemocnice Hradec Kralové - Nefrologická klinika
Hradec Králové, Hradec Králové Region, Czechia
CHU de Brest - Hopital La Cavale Blanche - Service de Nephorologie-Hémodialyse-Transplantation
Brest, Brittany Region, France
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades - Service d'Hopital De Jour Néphrologie adulte
Paris, Île-de-France Region, France
Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Nephrologie et transplantation d'organes
Toulouse, Occitanie, France
Charité Mitte - Nephrologie und Internistische Intensivmedizin
Berlin, Germany
Universitaetsklinikum Erlangen - Medizinische Klinik 4, Nephrologie, Hypertensiologie
Erlangen, Bavaria, Germany
Universitaetsmedizin Goettingen (UMG) - Klinik fuer Nephrologie und Rheumatologie
Göttingen, Lower Saxony, Germany
Universitaetsklinikum Koeln - Klinik II fuer Innere Medizin - Nephrologie, Rheumatologie, Diabetologie, Innere Medizin
Cologne, North Rhine-Westphalia, Germany
Mavani Research Center
Ahmedabad, Gujarat, India
All India Institute of Medical Sciences (AIIMS) - New Delhi
New Delhi, National Capital Territory of Delhi, India
K.G. Hospital
Coimbatore, Tamil Nadu, India
The Institute of Post Graduate Medical Education & Research (IPGMER) (SSKM Hospital)
Kolkata, West Bengal, India
Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto
Bologna, Emilia-Romagna, Italy
Ospedale Pediatrico Bambino Gesù - Nefrologia
Rome, Lazio, Italy
IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene
Genoa, Liguria, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia
Brescia, Lombardy, Italy
Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
Osaka, Japan
Japanese RedCross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan
Saitama Prefectural Children's Medical Center
Chuo-Ku, Tokyo, Japan
Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych
Poznan, Greater Poland Voivodeship, Poland
Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych
Warsaw, Masovian Voivodeship, Poland
Hospital de Curry Cabral - Nephrology Department
Lisbon, Portugal
Unidade Local de Saúde de São João E.P.E. - Hospital São João - Serviço de Nefrologia
Porto, Portugal
Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department
Vila Nova de Gaia, Porto District, Portugal
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.